Search Results - Anthony W. Tolcher

Refine Results
  1. 1
    Antibody drug conjugates: lessons from 20 years of clinical experience

    Antibody drug conjugates: lessons from 20 years of clinical experience by Anthony W. Tolcher

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point

    The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point by Anthony W. Tolcher

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides

    Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides by Hideaki Miayake, Anthony W. Tolcher, Martin Gleave

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

    Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors by Anthony W. Tolcher, Wei Peng, Emiliano Calvo

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

    Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model by Suet Yi Leung, Hideaki Miyake, Tobias Zellweger, Anthony W. Tolcher, Martin Gleave

    Published 2001
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer

    Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer by Ian M. Thompson, Catherine M. Tangen, Anthony W. Tolcher, E. David Crawford, Mario A. Eisenberger, C. M. Moinpour

    Published 2001
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

    A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer by Anthony W. Tolcher, Leonard J. Appleman, Geoffrey I. Shapiro, Alain C. Mita, Frank Cihon, Arthur Mazzu, P. R. Sundaresan

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

    Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors by Robert H. Vonderheide, Jennifer M. Burg, Rosemarie Mick, Jennifer A. Trosko, Dongguang Li, M. Naveed Shaik, Anthony W. Tolcher, Omid Hamid

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

    A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors by David C. Smith, Rashmi Chugh, Amita Patnaik, Kyriakos P. Papadopoulos, Min Wang, Ann M. Kapoun, Lu Xu, Jakob Dupont, Robert Stagg, Anthony W. Tolcher

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series by Noboru Yamamoto, Anthony W. Tolcher, Navid Hafez, Iwona Ługowska, Rodryg Ramlau, Teresa Macarulla, Junxian Geng, Jian Li, Michael Teufel, Angela Märten, Patricia LoRusso

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

    Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA by Jonathan E. Zuckerman, Ismael Gritli, Anthony W. Tolcher, Jeremy D. Heidel, Dean Lim, Robert J. Morgan, Bartosz Chmielowski, Antoni Ribas, Mark E. Davis, Yun Yen

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors

    Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors by Anthony W. Tolcher, Joshua Brody, Nishanthan Rajakumaraswamy, Michelle Kuhne, Torsten Trowe, Anees M. Dauki, Shantheri Pai, Ling Han, Kai-Wen Lin, Michael Petrarca, Shivaani Kummar

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer

    Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer by Amita Patnaik, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Muralidhar Beeram, Saı̈k Urien, Larry J. Schaaf, Sanaa Tahiri, Tanios Bekaii‐Saab, François Lokiec, Keyvan Rezaï, Aby Buchbinder

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

    Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles by Mark E. Davis, Jonathan E. Zuckerman, Chung Hang Jonathan Choi, David B. Seligson, Anthony W. Tolcher, Christopher A. Alabi, Yun Yen, Jeremy D. Heidel, Antoni Ribas

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study by Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle D. Holen, Garry Schwartz, Mark R. Albertini, Geoffrey R. Weiss, Salim Yazji, Chee M. Ng, George Wilding

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

    First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors by Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gataree Ngarmchamnanrith, Erik Rasmussen, Benny Amore, Dirk Nagorsen, John S. Hill, Joe Stephenson

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

    First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors by Timothy A. Yap, Anthony W. Tolcher, Ruth Plummer, Jatinder Kaur Mukker, Marta Enderlin, Christine Hicking, Thomas Grombacher, Giuseppe Locatelli, Zoltán Szűcs, Ioannis Gounaris, Johann S. de Bono

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

    Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma by Amita Patnaik, Glen J. Weiss, K. Papadopoulos, Craig C. Hofmeister, Raoul Tibes, Anthony W. Tolcher, Robin Isaacs, J. Jac, May Han, Francis Payumo, Monette Cotreau, Rajesh Ramanathan

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma

    A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma by Monica Mita, Patricia LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita, Roberta Ferraldeschi, Harold Keer, Aram Oganesian, Xiang Yao Su, Simone Jueliger, Anthony W. Tolcher

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

    Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors by Cristiana Sessa, Patricia LoRusso, Anthony W. Tolcher, Françoise Farace, Nathalie Lassau, Angelo Delmonte, Antonio Braghetti, Rastislav Bahleda, Patrick Cohen, Marie Hospitel, Christine Veyrat‐Follet, Jean‐Charles Soria

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: